In The News

In Bloomberg BNA Medical Research Law & Policy Report,Litigators Review Corruption Risks Facing Sponsors and Service Providers in the Clinical Trial Industry

Practices: Health Care, Anti-Corruption / International Risk

Health care partner Mark Barnes (Boston) business & securities litigation partner Nicholas Berg, and government enforcement associate Brendan Hanifin (both of Chicago) co-authored an article published by Bloomberg BNA’s Medical Research Law & Policy Report on Jan. 6. The article, titled “Corruption Risks in International Clinical Trials: Navigating Between Anti-Bribery Laws and Local Circumstances,” examines corruption risks in international clinical trials and discusses several proactive steps that clinical trial sponsors and services providers may consider to mitigate the risk.

Cookie Settings